BioSpace News Archive

Detailed results from Eli Lilly and Company’s phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in Nature Medicine and simultaneously presented at ObesityWeek® 2023.

Samsung Bioepis Co., Ltd. presented two clinical study data for SB16, a proposed biosimilar to Prolia, at the American Society for Bone and Mineral Research 2023 Annual Meeting being held from October 13 to 16 in Vancouver, BC, Canada.

Everest Medicines announced that its licensing partner, Pfizer Inc. has received approval from the U.S. Food and Drug Administration for VELSIPITY™, an oral, once-daily, selective sphingosine-1-phosphate receptor modulator for adults with moderately to severely active ulcerative colitis.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that it will host a conference call to discuss a business update on Monday, October 16, 2023 at 7:30 a.m. ET.

Ascentage Pharma announced that it has entered into a clinical collaboration with AstraZeneca Investment Co., Ltd.

Eisai Co. Ltd announced that the company will present new data from the phase 3 Clarity AD study for its Alzheimer’s disease treatment LEQEMBI® 100 mg/mL injection for intravenous use and new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer’s Disease conference.

Immunic, Inc. announced the presentation of data from the company’s phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, in patients with celiac disease in a moderated poster session at the United European Gastroenterology Week 2023, taking place October 14-17 in Copenhagen.

Regeneron Pharmaceuticals, Inc. announced the latest clinical data in early- and late-stage cancers from its oncology pipeline will be presented at the European Society for Medical Oncology Congress 2023 from October 20 to 24 in Madrid, Spain.

Burning Rock Biotech Limited is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US FDA for its OverC™ Multi-Cancer Detection Blood Test in January 2023, its OverC™ MCDBT has been granted Breakthrough Device Designation by the China NMPA.